← Back to Search

Rho-Kinase Inhibitor

Netarsudil for Retinal Detachment

Phase 2 & 3

Recruiting

Led By Jason Hsu, MD

Research Sponsored by Wills Eye

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up six months

Awards & highlights

Study Summary

This trial will test if a drug called netarsudil can prevent scar tissue from forming after retinal detachment repair in patients at high risk.

Who is the study for?

This trial is for adults with a specific type of retinal detachment at high risk for scar tissue formation after surgery. Participants must be willing to follow the study plan and have had no prior significant eye surgeries, except cataract extraction.Check my eligibility

What is being tested?

The study tests if netarsudil can prevent scar tissue in eyes at risk after retinal detachment repair. Patients will receive netarsudil or a control solution post-surgery to see which is more effective in preventing proliferative vitreoretinopathy.See study design

What are the potential side effects?

Netarsudil may cause side effects like redness, discomfort in the eye, cornea problems, and changes in vision. The severity of these side effects varies from person to person.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ six months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~six months

This trial's timeline: 3 weeks for screening, Varies for treatment, and six months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Single surgery anatomic success (retinal re-attachment) rate

Secondary outcome measures

Change from baseline in visual acuity (Snellen) wearing habitual correction.

Number of participants with treatment-related adverse events as assessed on ophthalmic examination at all time points.

The number of participants with an epiretinal membrane as assessed on ocular examination or optical coherence tomography imaging

+1 more

Trial Design

2Treatment groups

Experimental Treatment

Placebo Group

Group I: Netarsudil 0.02%Experimental Treatment1 Intervention

For the study arm: one drop of rho-kinase (ROCK) inhibitor in the vitrectomized eye, once daily in the evening starting on postoperative day 1 after RRD repair surgery, till post-operative day 56

Group II: Artificial tearsPlacebo Group1 Intervention

Patients enrolled in the control group will receive a placebo (one drop of artificial tears) once daily in the evening starting on postoperative day 1 after RRD repair surgery, till post-operative day 56

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Wills EyeLead Sponsor

79 Previous Clinical Trials

10,356 Total Patients Enrolled

Jason Hsu, MDPrincipal InvestigatorWills Eye Physicians-Mid Atlantic Retina, Wills Eye Hospital

9 Previous Clinical Trials

219 Total Patients Enrolled

Media Library

Netarsudil 0.02% Ophthalmic Solution [RHOPRESSA] (Rho-Kinase Inhibitor) Clinical Trial Eligibility Overview. Trial Name: NCT05660447 — Phase 2 & 3

Proliferative Vitreoretinopathy Research Study Groups: Netarsudil 0.02%, Artificial tears

Proliferative Vitreoretinopathy Clinical Trial 2023: Netarsudil 0.02% Ophthalmic Solution [RHOPRESSA] Highlights & Side Effects. Trial Name: NCT05660447 — Phase 2 & 3

Netarsudil 0.02% Ophthalmic Solution [RHOPRESSA] (Rho-Kinase Inhibitor) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05660447 — Phase 2 & 3

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Does this research currently accept participants?

"Clinicaltrials.gov has reported that this particular trial is not currently recruiting participants, despite being initially posted on December 19th 2022 and last amended upon December 13th 2022. However, there are 30 other medical studies actively looking for patients at the time of writing."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

A Multi-Center Study on the Use of Rho-Kinase Inhibitor to Reduce or Prevent PVR in RRD Eyes at High Risk for PVR

Jason Hsu, MD 2023. "A Multi-Center Study on the Use of Rho-Kinase Inhibitor to Reduce or Prevent PVR in RRD Eyes at High Risk for PVR". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05660447.